Peptide directory

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg, AEDR) typically described in patents as a myocardium-restoring peptide. The retrieved literature is almost entirely preclinical — rodent tissue and cultured cells — with no defined receptor and no modern clinical development.

Follistatin-344 is the 344-amino-acid precursor form of follistatin, a secreted glycoprotein. In human translational work it is most often encountered as an AAV-delivered transgene (AAV1.CMV.huFollistatin344), not as an injectable peptide — a distinction that materially affects how mechanism, dosing, and safety should be interpreted.

Methylene blue is an oxidation-reduction thiazine dye. In the U.S., PROVAYBLUE is an FDA-approved methylene blue injection for methemoglobinemia. Low-dose mitochondrial or neurocognitive uses are widely discussed elsewhere, but the strongest evidence and clearest regulatory footing remain the approved hematologic indication.

PEG-MGF is a pegylated MGF derivative intended to preserve or extend the activity window of native MGF-like signaling. The design rationale (PEGylation as a half-life-extension strategy) is scientifically reasonable, but that does not mean PEG-MGF itself has a validated human pharmacokinetic or therapeutic profile.

PNC-27 is a 32-residue chimeric p53-derived anticancer peptide that fuses the p53 residues 12–26 HDM-2-binding domain (PPLSQETFSDLWKLL) to a membrane-penetrating / membrane-residency sequence. It selectively binds HDM-2/MDM2 expressed on cancer-cell membranes, induces transmembrane pore formation, and causes necrotic lysis. No human clinical dataset was identified in the source material.

Protirelin is synthetic thyrotropin-releasing hormone (TRH). Historically used as a diagnostic pituitary-thyroid challenge agent. Current U.S. public labeling on DailyMed reflects a compounded product, and PubChem notes protirelin is not currently available in an FDA-approved product.

SLU-PP-332 is an experimental small molecule (not a peptide). Primary reports describe it as a synthetic agonist of ERRα/β/γ, with highest potency for ERRα. Follow-on medicinal chemistry emphasizes that the parent compound lacks oral bioavailability, motivating development of orally active follow-up agonists. There is no approved human use.

Triptorelin is a GnRH agonist FDA-approved as TRELSTAR for advanced prostate cancer. Non-U.S. labeling extends use to endometriosis, fibroids, hormone-responsive breast cancer, infertility protocols, and central precocious puberty (Decapeptyl).

VIP is an endogenous neuropeptide with broad vasoactive, pulmonary, gastrointestinal, and immunomodulatory functions. The main synthetic therapeutic analog in the literature is aviptadil (Zyesami). It remains investigational in the U.S. rather than FDA-approved.